CN106011289B - The diagnosis and treatment target of LILRA2 gene and its expression product as Huppert's disease - Google Patents
The diagnosis and treatment target of LILRA2 gene and its expression product as Huppert's disease Download PDFInfo
- Publication number
- CN106011289B CN106011289B CN201610602004.6A CN201610602004A CN106011289B CN 106011289 B CN106011289 B CN 106011289B CN 201610602004 A CN201610602004 A CN 201610602004A CN 106011289 B CN106011289 B CN 106011289B
- Authority
- CN
- China
- Prior art keywords
- lilra2
- gene
- disease
- huppert
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses the molecular markers that LILRA2 gene can be used as Diagnosis of Multiple Myeloma.There are significant differences for expression in normal bone marrow tissue and Huppert's disease tissue using genetic chip and QPCR experiment discovery LILRA2 gene expression product by the present invention, it can judges whether subject suffers from Huppert's disease or with the risk for suffering from Huppert's disease by LILRA2 expression conditions in detection myeloid tissue.According to the correlation of the two, the present invention develops a kind of kit for diagnosing Huppert's disease.Diagnostic kit of the invention can be used for the early diagnosis of disease, clinically be with a wide range of applications.In addition, providing the foundation the invention also discloses the molecular target that LILRA2 gene can be used as treatment Huppert's disease to carry out the development of multiple myeloma drug.
Description
Technical field
The present invention relates to diagnosing tumor, treatment, prediction prognosis fields, more particularly it relates to detect LILRA2
Abnormal is diagnosing tumor, the prediction method of prognosis of means；And the tumor therapeutic agent of activation LILRA2 gene or protein.
Background technique
Huppert's disease (multiple myeloma, MM) is a kind of hematological system of thick liquid cell paraplasm in marrow
Malignant neoplastic disease accounts for about hematologic malignancies 10%, is apt to occur in the elderly, with China human mortality aging, MM morbidity people
Number increased.It is mainly characterized by Clonal thick liquid cell paraplasm and invades marrow, generates Clonal immunoglobulin.Face
Bed shows as myeloma cell's hyperplasia, infiltration and bone marrow microenvironment are destroyed, cause anaemia, bleeding, ostalgia or fracture, high calcium disease,
Renal insufficiency and immunologic hypofunction etc..β 2-MG is the common clinical indices of multiple myeloma patients, and as the world
One of the index of staging scale (ISS), β 2-MG level with patients with malignant myeloma tumor load, there are correlations for prognosis.Treatment at present
Myeloma mainly applies hormone, proteasome inhibitor, immunomodulator etc., and the treatment of these drugs can be such that MM alleviates, but
Final inevitably recurrence, it is therefore desirable to find new diagnosing and treating strategy.
Summary of the invention
It is more to diagnose by detection LILRA2 gene or protein expression difference that one of the objects of the present invention is to provide one kind
The method of hair property myeloma.
The second object of the present invention is to provide a kind of more to predict by detection LILRA2 gene or protein expression difference
The method of hair property myeloma prognosis.
The third object of the present invention is to provide a kind of multiple to treat by activation LILRA2 gene or LILRA2 albumen
The method of property myeloma.
The fourth object of the present invention is to provide a kind of method for screening the drug for the treatment of Huppert's disease.
The fifth object of the present invention is to provide a kind of for treating the drug of Huppert's disease.
To achieve the goals above, present invention employs following technical solutions:
The present invention provides the products of detection LILRA2 gene or LILRA2 albumen to prepare Diagnosis of Multiple Myeloma work
Purposes in tool.
The present invention also provides the products of detection LILRA2 gene or LILRA2 albumen to predict Huppert's disease in preparation
Purposes in prognostic tool.
Further, the product of the detection LILRA2 gene or LILRA2 albumen includes detection LILRA2 gene or LILRA2
The product of the expression of albumen.The product includes that can combine the nucleic acid of LILRA2 gene or can combine LILRA2 egg
White substance (such as antibody).The nucleic acid is able to detect the expression of LILRA2 gene；The substance is able to detect
The expression of LILRA2 albumen.
The product of detection LILRA2 gene of the invention can play its function based on the known method of nucleic acid molecules is used:
As PCR, such as Southern hybridization, Northern hybridization, dot blot, fluorescence in situ hybridization (FISH), DNA microarray, ASO method,
High-flux sequence platform etc..It can qualitatively, quantitatively or semi-quantitatively implement analysis using the product.
Include that nucleic acid in the said goods can be obtained by chemical synthesis, or by containing from biomaterial preparation
It is expected that the gene of nucleic acid, then using primer amplification designed for amplification expectation nucleic acid, it is obtained.
Further, the PCR method is known method, for example, ARMS (Amplification Refractory
Abruptly-changing system is not answered in Mutation System, amplification) method, RT-PCR (reverse transcriptase-PCR) method, nesting PCR method etc..Amplification
Nucleic acid can be by using dot blotting hybridization method, Surface Plasmon Resonance (SPR method), PCR-RFLP method, original position RT-PCR
Method, PCR-SSO (sequence specific oligonucleotide) method, PCR-SSP method, AMPFLP (amplifiable fragment length polymorphism) method,
MVR-PCR method and PCR-SSCP (single-strand conformation polymorphism) method detect.
Nucleic acid recited above includes the primer for expanding LILRA2 gene, and the primer for including in product can be by passing through
Synthesis is learned to prepare, by using those skilled in the art will know that method be suitably designed with reference to Given information, and pass through
It is prepared by chemical synthesis.
In specific embodiments of the present invention, the nucleic acid is amplimer used in QPCR experiment, the primer
Sequence such as SEQ ID NO.1 (positive sequence) and SEQ ID NO.2 (reverse sequence) shown in.
Nucleic acid recited above may also include probe, and the probe can be prepared by chemical synthesis, by using this
The method that field technical staff knows appropriately is designed with reference to Given information, and is prepared by chemical synthesis, or can lead to
The gene for containing desired nucleic acid sequence from biomaterial preparation is crossed, and is expanded using the primer designed for amplification expectation nucleic acid sequence
Increase it to prepare.
The product of detection LILRA2 albumen of the invention can play its function: example based on the known method of antibody is used
It such as, may include ELISA, radioimmunoassay, immunohistochemical method, western blot etc..
The product of detection LILRA2 albumen of the invention includes the antibody or its segment for specifically binding LILRA2 albumen.It can
To use the antibody or its segment of any structure and size, immunoglobulin class, origin etc., as long as it is in conjunction with target protein
It can.The antibody or its segment for including in testing product of the invention can be monoclonal or polyclonal.Antibody fragment refers to guarantor
Stay peptide of the antibody to the active antibody of the combination of antigen a part of (Partial Fragment) or containing antibody a part.Antibody fragment can be with
Including F (ab ')2, Fab ', Fab, scFv (scFv), disulphide bonding Fv (dsFv) or its polymer, the area dimerization V
(double antibody) or peptide containing CDR.The product of detection LILRA2 albumen of the invention may include encoding antibody or encoding antibody
The isolated nucleic acid of the amino acid sequence of segment, the carrier comprising the nucleic acid, and carry the cell of the carrier.
Antibody can be obtained by the way that well known to a person skilled in the art methods.For example, preparation retains target all or in part
The mammalian cell expression vector of their polynucleotides of the polypeptide or integration coding of protein is as antigen.Exempted from using antigen
After epidemic disease animal, from the immune animal adaptive immune cell of process and myeloma cell is merged to obtain hybridoma.Then from hybridization
Tumor culture collects antibody.It finally can be real by using antibody of the LILRA2 albumen for being used as antigen or part thereof to acquisition
Antigentic specificity purifying is applied to obtain the monoclonal antibody for LILRA2 albumen.Polyclonal antibody can be prepared as follows: with
Identical antigen-immunized animal above collects blood sample from by immune animal, serum is isolated from blood, is then made
Implement antigentic specificity to serum with above-mentioned antigen to purify.It can be by the antibody that is obtained with enzymatic treatment or by using acquisition
The sequence information of antibody obtains antibody fragment.
The combination of marker and antibody or its segment can be implemented by method as commonly known in the art.For example, can
With following fluorescent marker protein or peptide: clean protein or peptide with phosphate buffer, addition DMSO, buffer, etc. standards
Standby dyestuff, then mixed solution, then at being placed at room temperature for 10 minutes.In addition, the labelling kit of commercialization can be used in label, it is all
Such as biotin labeling reagent box, such as biotin labeling reagent box-NH2, biotin labeling reagent box-SH
(DojindoLaboratories)；Alkali phosphatase enzyme mark kit such as alkali phosphatase enzyme mark kit-NH2, alkaline phosphorus
Sour enzyme labelling kit-SH (Dojindo Laboratories)；Peroxidase labelling kit such as peroxidase mark
Remember kit-NH2, peroxidase labelling kit-NH2 (Dojindo Laboratories)；Phycobniliprotein labelled reagent
Box such as phycobniliprotein labelling kit-NH2, phycobniliprotein labelling kit-SH, B- phycoerythrin labelling kit-NH2,
B- phycoerythrin labelling kit-SH, R-PE labelling kit-NH2, R-PE labelling kit SH
(DojindoLaboratories)；Fluorescent labeling reagent box such as fluorescein labelling kit-NH2, HiLyte Fluor (TM)
555 labelling kit-NH2,647 labelling kit-NH2 of HiLyte Fluor (TM) (Dojindo Laboratories)；And
DyLight 547 and DyLight647 (Techno Chemical Corp.), Zenon (TM), Alexa Fluor (TM) antibody
Labelling kit, Qdot (TM) antibody labeling kit (Invitrogen Corporation) and EZ- marker protein mark
Remember kit (Funakoshi Corporation).For correct labeling, suitable instrument can be used to detect by label
Antibody or its segment.
As the sample according to testing product of the invention, the tissue sample for example obtained from biopsy subject can be used
Or fluid.Sample is not particularly limited, as long as it is suitable for measurement of the invention；For example, it may include tissue, blood, blood plasma,
Serum, lymph, urine, serous cavity liquid, spinal fluid, synovia, aqueous humor, tear, saliva or its fraction or treated material
Material.
In specific embodiments of the present invention, tissue of the sample from subject.
In the present invention, " prognosis " refers to mistake of the tumor patient after inhibiting by surgical procedure etc. or alleviating tumour growth
Journey or result.In the present specification, prognosis can be by surgical procedure inhibit or alleviate tumour growth after 1,2,3,4,5,6,
7,8,9,10,15,20 years or more long when life state.Prognosis can be by checking biomarker, that is, LILRA2 albumen or volume
The gene of code LILRA2 albumen is predicted.Prognosis prediction can be performed such that according to biomarker with or without or increasing
Or reduce, determine that the prognosis of patient is good or bad, or determine the probability of good prognosis or poor prognosis.
In the present invention, " prognosis bona " refer to inhibit or alleviate for patient by surgical procedure etc. tumour growth it
Afterwards, patient's long-term (such as 3,5,6,7,8,9,10,15,20 years or longer) does not have critical condition.Alternatively, good prognosis can anticipate
Refer to and survives in such long-time, sent out again without transfer, without recurrence or nothing.For example, prognosis bona can mean at least 3 years or outstanding
It is to survive at least 5 years, preferably without transfer or recurrence.The most preferred state of prognosis bona is survival for a long time without disease.Such as
Used herein, " prognosis bona " can also include any such state, wherein it can be found that disease such as shifts, still
It is pernicious low and do not severely impact survival ability.
In the present invention, " prognosis mala " refers to that patient is short after inhibiting or alleviating tumour growth by surgical procedure etc.
Fatal condition occurs in period (such as 1,2,3,4,5 year or shorter).Alternatively, poor prognosis refers in such short-term extremely
It dies, shift, recur or sends out again.For example, poor prognosis can mean Preventive or dead at least 3 years or especially at least 5 years
It dies.
Prediction prognosis is referred to the process of prediction status of patient or as a result, is not meant to be predicted with 100% accuracy
The process or result of status of patient.Prediction prognosis refers to whether a possibility that determining certain processes or result increases, and simultaneously unexpectedly
Taste by determining a possibility that certain processes or result occurs or not compared with certain processes or result.Such as this
For invention, in the present invention in the horizontal patient reduced of LILRA2 gene or LILRA2 albumen, with the trouble for not showing this feature
Person compares, and more likely observes particular procedure or result.
Further, it is described detection LILRA2 gene or LILRA2 albumen product can be detection LILRA2 gene or
The reagent of LILRA2 albumen is also possible to include kit, chip, test paper of the reagent etc., is also possible to using the examination
The high-flux sequence platform of agent.
The present invention also provides it is a kind of diagnose Huppert's disease tool, the tool be able to detect LILRA2 gene or
The expression of LILRA2 albumen.The tool includes that can combine the nucleic acid of LILRA2 gene or can combine LILRA2 egg
White substance (such as antibody).The nucleic acid is able to detect the expression of LILRA2 gene；The substance is able to detect
The expression of LILRA2 albumen.
Further, the property of the nucleic acid and the substance is the same as noted earlier.
Further, the tool of the diagnosis Huppert's disease includes but is not limited to chip, kit, test paper or high pass
Measure microarray dataset；High-flux sequence platform is a kind of tool of special diagnosis Huppert's disease, with high-flux sequence skill
The development of art will become very easily work to the building of the gene expression profile of a people.By comparison Disease and just
The gene expression profile of ordinary person group, the exception for being easy to analyze which gene are related to disease.Therefore, know in high-flux sequence
The exception of the LILRA2 gene purposes for also belonging to LILRA2 gene related to Huppert's disease, equally in protection model of the invention
Within enclosing.
The present invention also provides a kind of tool for predicting Huppert's disease prognosis, the prediction Huppert's disease prognosis
Tool includes the nucleic acid that can combine LILRA2 gene or the substance (such as antibody) that can combine LILRA2 albumen.The core
Acid is able to detect the mRNA level in-site of LILRA2 gene；The substance is able to detect the expression of LILRA2 albumen.
Further, the property of the nucleic acid and the substance is the same as noted earlier.
Further, it is described prediction Huppert's disease prognosis tool include but is not limited to chip, kit, test paper or
High-flux sequence platform；High-flux sequence platform is a kind of tool of special diagnosis Huppert's disease, as high pass measures
The development of sequence technology will become very easily work to the building of the gene expression profile of a people.By comparing Disease
With the gene expression profile of normal population, the exception for being easy to analyze which gene is related to disease.Therefore, in high-flux sequence
The exception of the LILRA2 gene purposes for also belonging to LILRA2 gene related to Huppert's disease is known, equally in guarantor of the invention
Within the scope of shield.
The amino acid that anti-LILRA2 antibody used in testing product of the invention, diagnostic tool or its segment are identified
Number is not particularly limited, as long as antibody can combine LILRA2.
The present invention also provides a kind of diagnosis Huppert's disease or the method for predicting Huppert's disease prognosis, the sides
Method includes the following steps:
(1) sample of subject is obtained；
(2) expression of LILRA2 gene or albumen in Samples subjects is detected；
(3) it associates whether by the expression of the LILRA2 gene or albumen that measure with the illness of subject.
(4) compared with the control, the expression of LILRA2 gene or albumen reduces, then the subject is diagnosed as multiple
Myeloma or the subject are confirmed as prognosis mala.
The present invention also provides a kind for the treatment of method of Huppert's disease, the method includes activation LILRA2 gene or
LILRA2 albumen.
Further, the method includes promoting the expression of LILRA2 gene, or the expression or enhancing of promotion LILRA2 albumen
The activity of LILRA2 albumen.
The present invention also provides a kind of screening techniques of tumour medicine, can be by after adding testing drug to cancer cell
Or the expression of some period measurement LILRA2 gene or LILRA2 albumen after applying testing drug to tumor model animal
Level improves the effect of tumor prognosis to measure tumour medicine.More specifically, when LILRA2 gene or LILRA2 albumen
It is swollen as improving that the drug may be selected when increasing after adding or applying testing drug or when restoring normal level in expression
The therapeutic agent of tumor prognosis.
The present invention also provides a kind of drugs of activator containing LILRA2 gene or LILRA2 albumen.
The present invention also provides application of the above-mentioned activator in the drug of preparation treatment Huppert's disease.
The activator of LILRA2 gene or LILRA2 albumen of the invention is unrestricted, as long as can promote or enhance
LILRA2 or be related to the upstream LILRA2 or downstream pathway substance expression or activity, and for treatment the effective drug of tumour be
It can.
Further, the activator includes LILRA2 gene, LILRA2 albumen, promoted type miRNA, promoted type transcriptional control
The factor or promoted type target small molecule compound.
The activator further includes carrier or host cell comprising carrying LILRA2 gene.
On the one hand activator of the invention can be used for supplementing the missing or deficiency of endogenic LILRA2 albumen, by mentioning
The expression of high LILRA2 albumen, thus Huppert's disease caused by treating because of LILRA2 hypoproteinosis.On the other hand it can use
In the activity of enhancing LILRA2 albumen, to treat Huppert's disease.
Drug of the invention can be used as medicine and be administered alone or apply together with other medicines.It can be with medicine of the invention
The other medicines that object is applied together are unrestricted, as long as it does not damage therapeutic or preventive medicine effect of the invention i.e.
It can, it is preferred that the drug for treating or preventing tumour may include such as alkylating agent, such as ifosfamide, ring phosphinylidyne
Amine, Dacarbazine, Temozolomide, Nimustine, busulfan, procarbazine, melphalan and Ranimustine；Antimetabolite, such as
Enocitabine, capecitabine, Carmofur, Cladribine, gemcitabine, cytarabine, cytarabine octadecyl phosphate
(cytarabine ocfosfate), Tegafur, tegafur-Uracil, Tegafur gimeracil oteracil potassium, deoxidation fluorine urine
Glycosides, hydroxycarbamide, fluorouracil, fludarabine, pemetrexed, Pentostatin, mercaptopurine and methotrexate (MTX)；Plant alkaloid, it is all
As Irinotecan, Etoposide, Sobuzoxane, docetaxel, nogitecan, Palmer altruism, vinorelbine, eldisine and
Vincaleukoblastinum；Antitumor antibiotic, such as actinomycin D, Aclarubicin, Amrubicin, idarubicin, epirubicin, Zinostatin
Stimalamer, daunorubicin, Doxorubicin, pirarubicin, bleomycin, Peplomycin, mitomycin C and mitoxantrone；
Drug based on platinum, such as oxaliplatin, carboplatin, cis-platinum and Nedaplatin；Hormonal medicaments, such as Anastrozole, Exemestane,
Estramustine, ethinyloestradiol, chlormadinone, Goserelin, tamoxifen, dexamethasone, Toremifene, Bicalutamide, Flutamide,
Prednisolone, Fosfestrol, mitotane, methyltestosterone, Medroxyprogesterone, Mepitiostane, Leuprorelin and Letrozole；Biological respinse modification
Agent, such as interferon-' alpha ', interferon beta, interferon gamma, interleukin, ubenimex, dry BCG and lentinan；With molecular targeted medicine
Object, such as Imatinib (imatinib), Gefitinib (gefitinib), gemtuzumab, ozogamicin, Tamibarotene, song
Appropriate monoclonal antibody, Tretinoin, bortezomib (bortezomib) and Rituximab etc..
Drug of the invention can be prepared into various dosage forms as needed.Including but not limited to, percutaneous, mucous membrane, nose, buccal,
Tablet, solution, granule, patch, paste, capsule, aerosol or suppository sublingual or orally use.
The administration method of drug of the invention is unrestricted, as long as it can play desired therapeutic effect or preventive effect i.e.
Can, including but not limited to intravenously, in peritonaeum, intraocularly, intra-arterial, intrapulmonary is taken orally, in vesicle, intramuscular, intratracheally, subcutaneously
, local by pleura by skin, sucking, by mucous membrane, skin, stomach is intra-articular, intra-ventricle, rectum, vagina,
In skull, in urethra, in liver, in tumor.In some cases, it can systematically be administered.It is locally to be administered in some cases.
The dosage of drug of the invention is unrestricted, can as long as obtaining desired therapeutic effect or preventive effect
To carry out appropriate determination according to symptom, gender, age etc..Example can be used in the dosage of therapeutic agent or prophylactic agent of the invention
Such as the therapeutic effect of disease or preventive effect are determined as index.
In the context of the present invention, " diagnosis Huppert's disease " is both multiple including judging whether subject has suffered from
Property myeloma, also include judge subject with the presence or absence of suffer from Huppert's disease risk.
" treatment " used herein is covered treatment-related in such as mankind of the mammal with related disease or illness
Disease or morbid state, and include:
(1) prevent disease or morbid state occurs in mammals, especially when the mammal is susceptible in the disease
Diseased state, but when being not yet diagnosed with this morbid state；
(2) inhibit disease or morbid state, that is, prevent its generation；Or
(3) alleviate disease or morbid state, even if disease or morbid state subside.
Term " treatment " is usually directed to treatment mankind or animal (for example, being applied by animal doctor), wherein can reach certain pre-
The therapeutic effect of phase, for example, inhibiting the development (including reduce development speed, stop development) of illness, improving illness and healing
Illness.It further include the treatment as precautionary measures (such as prevention).To not yet development be illness but have development be the illness endanger
The purposes of the patient of danger, is also included in term " treatment ".
The advantages of the present invention:
It is of the invention to have found a kind of molecular marker for diagnosing Huppert's disease, it can be using the molecular marker
Huppert's disease occur early stage can be used as judging, provide the survival rate of patient.
In addition, the present invention is capable of providing significant information to determine treatment side for patient by the prognosis of prediction patient
Case strategy.
The therapeutic agent of activator including LILRA2 gene or albumen of the invention can be used as new Huppert's disease
Therapeutic agent.
Detailed description of the invention
Fig. 1 shows the influence that LILRA2 gene overexpression is proliferated multiple myeloma cells；
Fig. 2 shows the influence that LILRA2 gene overexpression invades multiple myeloma cells；
Fig. 3 shows the influence that LILRA2 gene overexpression migrates multiple myeloma cells.
Specific embodiment
The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this
It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip
Part, such as Sambrook et al., molecular cloning: laboratory manual (New York:Cold Spring HarborLaboratory
Press, 1989) condition described in, or according to the normal condition proposed by manufacturer.
1 genetic chip of embodiment screens difference expression gene
1, it draws materials:
Huppert's disease tissue: collecting MM Bone Marrow of Patients biopsy specimen totally 10 made a definite diagnosis, MM diagnostic criteria refering to " in
2011 revised edition of state's Huppert's disease diagnosis and treatment guide ".Male 5, female 5, the median age 59 years old in patient.
Normal bone marrow tissue: same time malnutritional anemia Bone Marrow of Patients biopsy specimen 10 are collected as control
Group, wherein male 5, female 5, the median age 53 years old.
2, the acquisition of RNA is organized
Total tissue RNA is extracted using Trizol one-step method.
3, the measurement of RNA purity and concentration
1 μ l of RNA solution, Instrument measuring OD260, OD280 are taken, RNA concentration is OD260 value × extension rate × 40/
1000, OD260/OD280 is calculated, ratio represents RNA solution purity is high in 1.7-2.0, -20 DEG C guarantors few containing impurity such as protein
It deposits.
4, RNA integrity detection
(1) 2 μ l RNA sample row, 1.5% agarose gel electrophoresis (80v, 15min) is taken；
(2) after separating zone, genefinder is dyed, and Zone electophoresis band is observed under blue light；
(3) as 28s/18s about 2:1, illustrate that RNA stablizes without degradation.
5, gene chip hybridization and scanning
After the linearized amplification of total serum IgE, cy3-UTP is marked, and the cRNAs after fluorescent marker uses RNEASY Mini Kit
Purifying, carries out fragmentation processing to the cRNAs marked with the RNA Fragmentation Reagents of Amhion.Using beauty
People's full genome chip of expression spectrum (4x 44K gene) of Agilent company, state, 65 DEG C of hybridization 17h in chip hybridization furnace, then
Elution, dyeing, finally use Agilent DNA MicroarrayScanner scanner scanning.
6, chip data processing and analysis
Chip after hybridization imports data to analysis software, for two groups of ratios after chip scanner reads data point
Natural logrithm absolute value be greater than 2.0 or the gene less than 0.5 as difference expression gene.
7, statistical procedures
Data analysis is carried out using 13.0 statistical software of SPSS, group difference compares using one-way analysis of variance method, P <
0.05 difference has significant.
8, result
Chip results are shown, filter out 489 differential expressions between Huppert's disease tissue and normal bone marrow tissue altogether
Gene, wherein expression up-regulation gene 215, expression lower gene 274.
2 large sample of embodiment verifies the difference expression gene filtered out
Consideration yet there are no the gene conduct studied about the gene with Huppert's disease correlation in the prior art
Candidate gene, at the same consider gene sequencing as a result, selection LILRA2 gene (its express in Huppert's disease tissue under
Adjust) it is verified.
1, sample collection
50, Huppert's disease tissue, 60, normal bone marrow tissue are collected according to the method for embodiment 1.
2, it is verified in mRNA level in-site
2.1 extract tissue RNA
Step is the same as embodiment 1.
2.2 reverse transcription
Reverse transcription system totally 20 μ L, including 2 μ g/2 μ L, 50U/ μ L Rnasin of cell total rna, 1 μ L, 5 × reverse transcription are anti-
Answer 4 μ L, 10m M d NTP of buffer, 2 μ l, 50 μ g/mL random primer 2 μ L (promega), 200U/ μ L M-MLV reverse transcription
18 μ L of μ L, DEPC of enzyme.
37 DEG C are reacted 60 minutes, 95 DEG C of reactions of termination in 5 minutes.CDNA saves or carries out PCR amplification at -80 DEG C.
2.3PCR
Reaction system (is purchased from Tiangeng biochemical technology (Beijing) according to Real Master Mix (SYBR Green) kit
Co., Ltd) configuration, SYBR reaction system 10 μ L, 20 × SYBR solution of totally 25 μ L, 2.5 × Real Master Mix
1.25 μ L, 0.5 μ L of upstream primer, 0.5 μ L of downstream primer, 10.75 μ L, cDNA2 μ L of deionized water.Reaction condition is 94 DEG C
5min, 94 DEG C of 45s, 60 DEG C of 1min, 30 circulations, if blank control.
The fluorescence signal of preceding 10 circulations of PCR reaction adjusts baseline to suitable place, each fluorescence is bent as autofluorescent background signal
The recurring number in line and baseline crosspoint is Ct value.According to Δ C (t)=C (t)Target gene-C(t)β-actin, Δ Δ C (t)=2-ΔC(t), calculate target gene and β-actin relative expression quantity.
PCR primer sequence is as follows:
LILRA2 gene primer sequence is as follows:
Upstream primer: 5 '-TACAGGTGCTATGCTTAT-3 ' (SEQ ID NO.1)；
Downstream primer: 5 '-GAGTGATGGCTTCTTAGA-3 ' (SEQ ID NO.2).
β-actin gene primer sequence is as follows:
Upstream primer: 5 '-CTGGCACCACACCTTCTACAAT-3 ' (SEQ ID NO.3)；
Downstream primer: 5 '-AATGTCACGCACGATTTCCCGC-3 ' (SEQ ID NO.4)
2.4 result
The results show that the mRNA level in-site of LILRA2 gene is bright in Huppert's disease tissue compared with normal bone marrow tissue
Aobvious to lower, relative expression quantity is 0.11 ± 0.03, and difference has statistical significance (P < 0.05).
3, it is verified on protein level
3.1 extract tissue total protein
The operation of protein extraction is carried out according to the specification of EpiQuik tissue/cell total protein extraction kit.
3.2Western blot detection
The protein quantification of extraction is subjected to SDS-PAGE electrophoresis, carry out later transferring film, closing, primary antibody is incubated for, secondary antibody is incubated for,
Colour developing.
3.3 statistical procedures
The gray value of protein band is analyzed using Image J software, using β-actin as internal reference, by LILRA2 egg
The gray value of informal voucher band is normalized.Result data is indicated in a manner of mean+SD, is used
SPSS13.0 statistical software is next for statistical analysis, and difference between the two is examined using t, it is believed that has system as P < 0.05
Meter learns meaning.
3.4 result
The results show that LILRA2 protein level significantly reduces in Huppert's disease tissue compared with normal bone marrow tissue,
Relative expression quantity is 0.35 ± 0.06, and difference has statistical significance (P < 0.05).
Embodiment 3LILRA2 gene overexpression
1, plasmid construction
According to the coded sequence of LILRA2 gene design amplimer, primer be designed as those skilled in the art institute it is ripe
Know.From cDNA library (clontech company, the article No.: the 638831) coding of the LILRA2 gene of amplification overall length at Human fetal spleen
Sequence, above-mentioned cDNA sequence are inserted into eukaryotic expression vector pcDNA3.1, connect the recombinant vector pcDNA3.1- of acquisition
LILRA2 is used for subsequent experimental.
2, the culture and transfection of multiple myeloma cells
2.1 cell culture
RPMI8226 cell, which uses, contains 15% fetal calf serum (FBS), penicillin 100U/ml, 100 μ g/ml of streptomysin
1640 culture medium of RPMI be placed in 37 DEG C, 5%CO2, cultivate under saturated humidity environment.
2.2 cell transfecting
(1) day before transfection is by 0.5-2*105A tumour cell is suspended in the not antibiotic culture medium of 500 μ l, inoculation
To 24 well culture plates.
(2) transfection same day cell density should reach 80%-90%, prepare following compound A: 1 μ g Plasmid DNA is diluted in nothing
In blood serum medium, mix gently；Compound B: taking 4 μ l Lipofectamine2000 to be diluted in serum free medium, mixes
It is even.
(3) compound A and B are mixed, is mixed gently, is incubated at room temperature.
(4) 100 μ l liposome compounds are added in tumour cell, mix gently up and down, cell is put into 37 DEG C
Containing 5%CO2Incubator is incubated for 5-7 hours.
(5) it is small to continue culture cell 18-24 for the growth medium for adding 1ml to contain 2 times of normal serums and antibiotic concentration
When.
3, the overexpression situation of detection pcDNA3.1-LILRA2 is tested using QPCR
3.1 extraction cell total rnas are operated using conventional method.
3.2 reverse transcription
Step is the same as embodiment 2.
3.3QPCR
Step is the same as embodiment 2.
3.4 result
The results show that pcDNA3.1-LILRA2 can be successfully overexpressed, relative expression quantity is 8.16 ± 0.95, difference tool
Statistically significant (P < 0.05).
3, Western blot experiment detection pcDNA3.1-LILRA2 is overexpressed situation
Step is the same as embodiment 2.
The results show that transfecting LILRA2 albumen in the cell of pcDNA3.1-LILRA2 compared with transfecting pcDNA3.1 group
Content obviously increases, and relative expression quantity is 4.43 ± 0.87, and difference has statistical significance (P < 0.05).
Measurement of the expression of embodiment 4LILRA2 gene to multiple myeloma cells proliferative capacity
1, step:
(1) by cell inoculation in 96 orifice plates, each concentration does 3 multiple holes；
(2) solution of MTT working concentration is added, with 37 DEG C of cell common incubation 4h；
(3) culture medium is removed, 200 μ l dimethyl sulfoxides are added to dissolve first a ceremonial jade-ladle, used in libation crystal；
(4) continuous 5d surveys OD570, and all experiments are repeated three times above, averaged；
2, result:
As a result as shown in Figure 1, compared with transfecting pcDNA3.1 group, pcDNA3.1-LILRA2 group cell proliferation rate is transfected
Obviously slow down, difference has statistical significance (P < 0.05).It is above-mentioned the experimental results showed that, LILRA2 gene expression inhibition is multiple
The proliferation of property myeloma cell.
Embodiment 7 detects influence of the LILRA2 gene expression to cell migration, invasion
1, Matrigel
1.1 experimental procedures:
(1) upper chamber is precoated with Matrigel (artificial basement membrane)；
(2) cell after planting transfection in upper chamber, inoculum density 5*104/ 100 μ l cells, in serum free medium
Middle culture 18h；
(3) cell is added in the RPMI-1640 culture medium of 0.1% FBS and cultivates 18h；
(4) 50 μ l Matrigel are drawn on ice；
(5) it is added in 150 μ l serum-free RPMI-1640 culture mediums of pre-cooling and mixes well；
(6) the 50 μ l of Matrigel mixed in (5) is taken respectively, is added to transwell upper chamber, is covered entire film；
(7) 37 DEG C, to overnight, make Matrigel polymerize plastic；
(8) cell is washed 2 times with serum-free RPMI-1640 culture medium, is added in the RPMI-1640 culture medium of serum-free,
To 100 μ l of total volume；
(9) (8) are uniformly added into Transwell upper chamber, between lower layer's culture solution and cell, avoid bubble；
(10) RPMI-1640 culture of the 500-600 μ l of room addition downwards containing 5%FBS, 37 DEG C, 5%CO2；
(11) liquid is exhausted after 48h, wipes the cell not penetrated, move to 100% methanol of cell of the lower surface of film
Fixed 30min, PBS are washed 2 times；
(12) 0.2% violet staining upper chamber 30min, PBS wash away uncalled crystal purple；
(13) it is counted under inverted microscope.
1.2 results:
Experimental result such as Fig. 2 is shown, compared with transfecting pcDNA3.1 group, transfects pcDNA3.1-LILRA2 group cell invasion
Number significantly reduces, and difference has statistical significance (P < 0.05).
2, migration experiment
2.1 experimental procedure
(1) precoating Matrigel artificial basement membrane is not needed in upper chamber.Cell after planting transfection in upper chamber is inoculated with dense
Degree is (1*105The μ l cell of)/100, cultivates 18h in serum free medium；
(2) cell is added in the serum-free RPMI-1640 culture medium of 0.1% FBS and cultivates 18h；
(3) 50 μ l Matrigel are drawn with the pipette tips of pre-cooling on ice；
(4) it is added in 150 μ l serum-free RPMI-1640 culture mediums of pre-cooling and mixes well；
(5) it takes the 50 μ l of Matrigel mixed in (4) to be added to Transwell upper chamber respectively, covers entire film；
(6) 37 DEG C, to overnight, make Matrigel polymerize plastic；
(7) cell is washed 2 times with serum-free RPMI-1640 culture medium, is added in the RPMI-1640 culture medium of serum-free,
To 100 μ l of total volume；
(8) (7) are uniformly added into Transwell upper chamber, between lower layer's culture solution and cell, avoid bubble, downward room adds
Enter RPMI-1640 of the 500-600 μ l containing 10%FBS to cultivate, 37 DEG C, 5%CO2；
(9) liquid is exhausted after 48h, wipes the cell not penetrated, the cell for moving to the lower surface of film is solid with 100% methanol
Determine 30min, PBS is washed 2 times；
(10) 0.2% violet staining upper chamber 30min, PBS wash away uncalled crystal purple；
(11) it is counted under inverted microscope.
2.2 result
Experimental result such as Fig. 3 is shown, compared with transfecting pcDNA3.1 group, transfects the cell migration of pcDNA3.1-LILRA2 group
Number significantly reduces, and difference has statistical significance (P < 0.05).
The above results show the migration and invasion of LILRA2 gene expression inhibition myeloma cell.
The explanation of above-described embodiment is only intended to understand method and its core concept of the invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will also be fallen into the protection scope of the claims in the present invention.
Claims (9)
1. the product for detecting LILRA2 gene or LILRA2 albumen is preparing the application in the tool for diagnosing Huppert's disease.
2. application according to claim 1, which is characterized in that the product of the detection LILRA2 gene or LILRA2 albumen
The product of expression including detection LILRA2 gene or LILRA2 albumen.
3. application according to claim 1 or 2, which is characterized in that the product includes that can combine LILRA2 gene
Nucleic acid can be in conjunction with the substance of LILRA2 albumen；The nucleic acid is able to detect the expression of LILRA2 gene；The object
Matter is able to detect the expression of LILRA2 albumen.
4. application according to claim 3, which is characterized in that the nucleic acid is specifically expanded used in real-time quantitative PCR
Increase the primer of LILRA2 gene as shown in SEQ ID NO.1 and SEQ ID NO.2.
5. application according to claim 1, which is characterized in that the tool include be able to detect LILRA2 gene or
The tool of the expression of LILRA2 albumen.
6. application according to claim 5, which is characterized in that the tool includes can be in conjunction with the nucleic acid of LILRA2 gene
Or it can be in conjunction with the substance of LILRA2 albumen；The nucleic acid is able to detect the expression of LILRA2 gene；The substance energy
Enough detect the expression of LILRA2 albumen.
7. application according to claim 6, which is characterized in that the nucleic acid is specifically expanded used in real-time quantitative PCR
Increase the primer of LILRA2 gene as shown in SEQ ID NO.1 and SEQ ID NO.2.
Application of the activator of 8.LILRA2 gene or LILRA2 albumen in the drug of preparation treatment Huppert's disease.
9. application according to claim 8, which is characterized in that the activator can promote or enhance LILRA2 or be related to
The expression or activity of the substance of the upstream LILRA2 or downstream pathway.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610602004.6A CN106011289B (en) | 2016-07-27 | 2016-07-27 | The diagnosis and treatment target of LILRA2 gene and its expression product as Huppert's disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610602004.6A CN106011289B (en) | 2016-07-27 | 2016-07-27 | The diagnosis and treatment target of LILRA2 gene and its expression product as Huppert's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106011289A CN106011289A (en) | 2016-10-12 |
| CN106011289B true CN106011289B (en) | 2019-10-11 |
Family
ID=57114022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610602004.6A Active CN106011289B (en) | 2016-07-27 | 2016-07-27 | The diagnosis and treatment target of LILRA2 gene and its expression product as Huppert's disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106011289B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023236583A1 (en) * | 2022-06-07 | 2023-12-14 | 北京大学 | Use of rpn11 marker in detection of myeloma and disease risk thereof, prognosis analysis and treatment medicament |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106868197B (en) * | 2017-04-24 | 2019-07-05 | 刘志国 | Application of the gene marker in Huppert's disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2390662A1 (en) * | 2010-05-27 | 2011-11-30 | Erasmus University Medical Center Rotterdam | Molecular classification of multiple myeloma |
| CN102251035B (en) * | 2011-07-05 | 2013-01-23 | 北京大学人民医院 | Quantitative detection kit for SSX-2 gene-based assisted diagnosis of multiple myeloma patients |
-
2016
- 2016-07-27 CN CN201610602004.6A patent/CN106011289B/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023236583A1 (en) * | 2022-06-07 | 2023-12-14 | 北京大学 | Use of rpn11 marker in detection of myeloma and disease risk thereof, prognosis analysis and treatment medicament |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106011289A (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105969901B (en) | Purposes of the MS4A6A as Huppert's disease diagnosis and treatment marker | |
| CN105907879B (en) | Carcinoma of endometrium biomarker | |
| CN106222259B (en) | A kind of molecular marker of diagnosis and treatment Huppert's disease | |
| CN105886659A (en) | DSTN gene and expression product thereof as diagnosis and treatment target of endometrial cancer | |
| CN106011289B (en) | The diagnosis and treatment target of LILRA2 gene and its expression product as Huppert's disease | |
| CN105969904B (en) | Huppert's disease biomarker | |
| CN106191283B (en) | The diagnosis and treatment product of Huppert's disease biomarker | |
| CN106011288B (en) | Huppert's disease diagnosis and treatment marker and its application | |
| CN106244705B (en) | Application of the ERC1 in preparation diagnosis or treatment hypopharyngeal cancer tool | |
| CN106906290A (en) | CDSN as Dendritic cell diagnosis and treatment target | |
| CN106011260B (en) | A kind of molecular marker of diagnosis and treatment carcinoma of endometrium | |
| CN106381329B (en) | The diagnosis and treatment target of C18orf8 gene and its expression product as hypopharyngeal cancer | |
| CN106119357B (en) | Application of the TNS11 in preparation diagnosis and treatment carcinoma of endometrium product | |
| CN106119358B (en) | The diagnosis and treatment product of carcinoma of endometrium biomarker | |
| CN106222257B (en) | Application of the IGSF6 in preparation diagnosis and treatment Huppert's disease product | |
| CN106947818A (en) | A kind of molecular marker of diagnosis and treatment adenocarcinoma of colon | |
| CN106947820A (en) | Purposes of the VCAN in adenocarcinoma of colon diagnosis and treatment | |
| CN106011291B (en) | A kind of molecular marker of diagnosis and treatment hypopharyngeal cancer | |
| CN105886660A (en) | Application of UHRF1 (ubiquitin-like, containing PHD and RING finger domains, 1) as endometrial cancer diagnosis and treatment marker | |
| CN106048031B (en) | Application of the SYNM in preparation diagnosis or treatment carcinoma of endometrium tool | |
| CN106011286B (en) | Hypopharyngeal cancer diagnosis and treatment marker and its application | |
| CN105969903B (en) | The diagnosis and treatment product of hypopharyngeal cancer biomarker | |
| CN107034270B (en) | CLIC3 as diagnosis and treatment target of lung adenocarcinoma | |
| CN107034271B (en) | Purposes of the DUOX1 as adenocarcinoma of lung diagnosis and treatment marker | |
| CN106947819A (en) | Adenocarcinoma of colon diagnosis and treatment mark |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant after: Beijing Yang Shen biology information technology company limited Address before: 100080 Beijing city Haidian District Shanyuan Street No. 1 cubic court building room 3103 Applicant before: Beijing Yang Shen biology information technology company limited |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211117 Address after: 266000 room 2503, Qianshan building, D2, Qingdao International Innovation Park Phase II, No.1 Keyuan Weiyi Road, Laoshan District, Qingdao City, Shandong Province Patentee after: Qingdao Yangshen biomedical Co.,Ltd. Address before: Room 1210, building 3, Ronghua Xintai building, 10 ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Patentee before: BEIJING MEDINTELL BIOMED Co.,Ltd. |
|
| TR01 | Transfer of patent right |